However, the combined therapy was linked to a marginally non-significant increase in myalgia and a slightly higher risk of gastrointestinal problems, which may have an impact on patient tolerance.
← all excerpts
Lipid profile and safety of rosuvastatin monotherapy versus rosuvastatin plus ezetimibe in high risk coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
1
—
—